Research
Hormonal
Combination pharmacological therapy, such as pramlintide/metreleptin, is promising for the treatment of obesity.
Practitioners may consider combination therapies like pramlintide/metreleptin as a potential treatment option for obesity.
StrongSupportsmedium confidence
Combination pharmacological therapy, such as pramlintide/metreleptin, for the treatment of obesity is very promising and is supported by encouraging weight loss results and improvement in metabolic makers in early-phase clinical studies.
Why this rating
Based on early-phase clinical studies mentioned in the abstract.
Source
Novel strategy for the use of leptin for obesity therapy
Charmaine S. Tam et al. · Expert Opinion on Biological Therapy · 2011
DOI 10.1517/14712598.2011.619974
reviewCited 42×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →